This is the authors' abstract. We don't add key points for this paper.
Fusarium spp. are able to cause a wide range of opportunistic infections in both immunocompromised and immunocompetent individuals. Thus, new therapeutic options should be considered. We evaluated the antifungal activity of three phytocompounds (cinnamaldehyde, CIN; carvacrol, CRV; and thymol, THY), as well as their activities when combined with amphotericin B (AMB), caspofungin (CAS), itraconazole (ITC) and voriconazole (VRC) against 20 clinical isolates of Fusarium. Broth microdilution (M38-A2) and checkerboard methodologies were used to obtain MICs (Minimum inhibitory concentration) and FICIs (Fractional Inhibitory Concentration Index), respectively. The MICs observed for the phytocompounds were: 20–80 for CIN, 40-> 320 for CRV and 40–320 µg/mL for THY. The most effective combinations (synergism rates) were: THY + CAS (96%), CRV + CAS (88%), THY + AMB (76%), CRV + AMB (68%), THY + VRC (68%) and CRV + VRC (60%). Our findings suggest that CRV and THY have potent activity when combined with CAS, AMB or VRC.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Venturini et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: